Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 2, 2004, Pages 197-204

  López, Begoña ^b   González, Arantxa ^b   Díez, Javier ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b NONE

Author keywords

Arterial hypertension; Collagen; Fibrosis; Heart failure; Hypertensive heart disease; Matrix metalloproteinases

Indexed keywords

COLLAGEN; COLLAGENASE; COLLAGENASE 3; GELATINASE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

COLLAGEN SYNTHESIS; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART FAILURE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

FIBROSIS; HEART DISEASES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 1642365737     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200403000-00008     Document Type: Review

References (69)

1. Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997; 17:467-491.
2. Bode W, Maskos K. Structural basis of matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem 2003; 384:863-872. This is an excellent review of the structural characteristics of the different groups of MMPs and their tissue inhibitors. The authors give a physiologically oriented review.
3. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Circ Res 2003; 92:827-839. This paper provides a comprehensive review of the functional properties of the different groups of MMPs and their tissue inhibitors. It ties together the information from numerous biochemical studies.
4. Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens 2003; 21:1627-1630. This interesting short review is intended to increase the awareness and understanding of the role of MMPs in hypertensive renal damage, more specifically glomerular and interstitial fibrosis.
5. Bobik A, Tkachuk V. Metalloproteinases and plasminogen activators in vessel remodelling. Curr Hypertens Rep 2003; 5:466-472. This article outlines the contribution of MMPs to vascular remodeling associated with a number of clinical conditions, including arterial hypertension.
6. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102:1944-1949.
7. Monfort I, Perez-Tamayo R. The distribution of collagenase in normal rat tissues. J Histochem Cytochem 1975; 23:910-920.
8. Tyagi SC, Kumar S, Borders S. Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in normal and transformed fibroblast cells. J Cell Biochem 1996; 61:139-151.
9. Lees M, Taylor DJ, Wooley DE. Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinase A and B. Eur J Biochem 1994; 223:171-177.
10. Coker ML, Jolly JR, Joffs C, et al. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am J Physiol Heart Circ Physiol 2001; 281:H543-H551.
11. Tyagi SC, Matsubara L, Weber KT. Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem 1993; 26:191-198.
12. Gunasinghe SK, Spinale FG. Myocardial basis for heart failure: role of the cardiac interstitium. In: Mann D, editor. Heart failure. Philadelphia: W. B. Saunders; 2004. pp. 57-69. This is a comprehensive and updated review on the mechanisms and consequences of myocardial ECM remodeling that occurs in several cardiac conditions associated with heart failure, including HHD.
13. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of myocardial fibrosis in normal, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55:575-581.
14. Olivetti G, Melissari M, Balbi T, et al. Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 1994; 28:1199-1208.
15. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16:1031-1041.
16. Ciulla M, Paliotti R, Hess DB, et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10:657-664.
17. Schwartzkopff B, Brehm M, Mundehenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36:220-225.
18. Brilla CG, Funck RC, Rupp RH. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102:1388-1393.
19. Querejeta R, Varo N, López B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101:1729-1735.
20. Pardo-Mindán FJ, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J 1993; 14 (Suppl J):12-14.
21. Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin 2000; 18:435-442.
22. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15:264-272.
23. Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res 1999; 42:27-44.
24. Amanuma S, Sekiguchi M, Ogasawara S, et al. Biventricular endomyocardial biopsy findings in essential hypertension of graded severity. Postgrad Med J 1994; 70 (Suppl 1):S67-S71.
25. Pearlman ES, Weber KT, Janicki JS, et al. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest 1982; 46:158-164.
26. Brilla CG, Funck RC, Rupp RH. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102:1388-1393.
27. Lopez B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104:286-291.
28. Diez J, Querejeta R, López B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105:2512-2517.
29. Díez J, López B, Gonzalez A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 2001; 16:328-335.
30. Laviades C, Varo N, Fernández J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98:535-540.
31. Marin F, Roldan V, Climent V, et al. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34:1181-1186. This is an interesting report on the association of diminished MMP-1 activity with one potential complication of myocardial fibrosis in hypertension (i.e. atrial fibrillation).
32. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40:136-141. The authors report the association of increased levels of the tissue inhibitor of MMP-1 with alterations in echocardiographic parameters assessing diastolic filling in patients with hypertension.
33. Timms PM, Wright A, et al. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002; 15:269-272. The authors describe the association of increased levels of the tissue inhibitor of matrix metalloproteinase-1 with the severity of left ventricular growth in hypertensive patients.
34. Li-Saw-Hee FL, Edmunds E, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and antihypertensive therapy. Int J Cardiol 2000; 75:43-47.
35. Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix metalloproteinase 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17:119-124. The authors report that changes in the levels of circulating gelatinases are clearly dissociated from changes in the level of MMP-1. Thus, this paper points to two different patterns for MMP regulation and activity in hypertension.
36. López B, Gonzalez A, Varo N, et al. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38:1222-1226.
37. Brilla CG, Moderer S, Salge U, Heidtmann HH. Collagenolytic activity in left ventricular endomyocardial biopsies of patients with hypertensive heart disease or hypertrophic cardiomyopathy. Circulation 1994; 90 (Pt 2):1422.
38. Nagatomo Y, Caribello BA, Coker ML, et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol 2000; 278:H151-H161.
39. Gonzalez A, López B, Querejeta R, Díez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol 2002; 34:1585-1593. This is a comprehensive review of the different mechanisms by which angiotensin II may contribute to fibrosis in HHD. Special attention is paid to the ability of this peptide to inhibit collagen degradation.
40. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993; 73:413-423.
41. Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial matrix remodeling in hypertensive heart disease. Adv Exp Mol Biol 1997; 432:35-44.
42. Chua CH, Hamdy RC, Chua BH. Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Biochem Biophys Acta 1996; 1311:175-180.
43. 1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35:1197-1202.
44. 1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens 2003; 21:2085-2092. This paper outlines a genetic predisposition to developing altered collagen type I turnover, including depressed degradation, and myocardial fibrosis in a subgroup of patients with HHD.
45. Dostal DE. Regulation of cardiac collagen content. Angiotensin and cross-talk with local growth factors. Hypertension 2001; 37:841-844.
46. Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6:1899-1904.
47. Chua CC, Chua BH, Zhao ZY, et al. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res 1991; 26:271-281.
48. 1) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest 2002; 32:295-303.
49. Kawano H, Do YS, Kawano Y, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101:1130-1137.
50. Kobayashi N, Nakano S, Mita S, et al. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp Ther 2002; 301:459-466.
51. Yamamoto K, Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 1998; 68:371-385.
52. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular diseases. Circ Res 1995; 77:863-868.
53. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 2002; 34:1577-1584. This paper provides a critical appraisal of the available information on the potential role of aldosterone in induction of myocardial fibrosis through both a direct mineralocorticoid-receptor-mediated action and cross-talk with other profibrotic factors (e.g. angiotensin II and endothelin-1)
54. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26:809-820.
55. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000; 46:214-224.
56. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. FASEB J 1997; 11:51-59.
57. Janicki JS. Collagen degradation in the heart. In: Eghbali-Webb M, editor. Molecular biology of collagen matrix in the heart. Austin: Landes; 1995. pp. 61-76.
58. 2+. FEBS Lett 1988; 238:343-346.
59. 2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci 2000; 67:2257-2265.
60. Iwanaga Y, Aoyama T, Kihara Y, et al. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002; 39:1384-1391.
61. Camp TM, Smiley LM, Hayden MR, Tyagi SC. Mechanisms of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens 2003; 21:1719-1727. This is an interesting report on the potential role of gelatinases in the induction of glomerular sclerosis and interstitial fibrosis in a genetic model of hypertension.
62. Boxiel C, Fontaine V, Rücker-Mrtin C, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 2003; 42:336-344. The authors report findings that suggest that upregulation of gelatinase MMP-2 appears to be involved in fibrosis of the left atria that develops in rats with myocardial infarction.
63. Grote K, Flach I, Luchtefeld M, et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res 2003; 92:e80-e86.
64. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001; 280:C53-C60.
65. Fraccarollo D, Bauersachs J, Kellner M, et al. Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono-versus combination therapy. Cardiovasc Res 2002; 54:85-94.
66. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-satt hypertensive rats: role of ET(A) receptors. Hypertension 2002; 39 (2 Pt 2):679-684.
67. Kinugawa S, Tsutsui H, Hayashidani S, et al. Treatment with dimethylthiourea prevents left ventricular remodelling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000; 87:392-398.
68. Vasku A, Goldbergova M, Holla LI, et al. Two MMP-2 promoter polymorphisms (-790T/G and -735C/T) in chronic heart failure. Clin Chem Lab Med 2003; 41:1299-1303. This paper outlines the contributory role of genetic control of MMP expression in different cardiomyopathies.
69. Spinale FG. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res 2002; 90:520-530.